[1] Heald P,Yan SL,Edelson R.Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma.Arch Dermatol,1994,130:198-203. [2] Hoppe RT,Medeiros LJ,Warnke,et al.CD8-positive tumorinfiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides.J Am Acad Dermatol,1995,32:448-453. [3] Berger CL,Wang N,Christensen I,et al.The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens.J Invest Dermatol,1996,107:392-397. [4] Longley J,Tyrrell L,Lu SZ,et al.Malignant and normal T cells show random use of T-cell receptor α chain variable regions in patients with cutaneous T-cell lymphoma.J Invest Dermatol,1995,105:62-64. [5] Rammensee HG,Friede T.MHC ligands and peptides motifs:first list-ing.Immunogenetics,1995,41:178-228. [6] Falk K,Rotzschke O.Consensus motifs and peptide ligands of MHC class I molecules.Semin Immunol,1993,5:81-94. [7] Traversari C,Van der Bruggen P,Van den Eynde B,et al.Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytotoxic T lymphocytes.Immunogenetics,1992,35:145-152. [8] Kawakami Y,Nishimura MI,Restifo NP,et al.T-cell recognition of human melanoma antigens.J Immunother,1993,14:88-93. [9] Ben-Nun A,Wekerle H,Cohen IR.Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein.Nature,1981,292:60-61. [10] Bourdette DN,Whitham RH,Chou YK,et al.Immunity to TCR peptide in multiple sclerosis.I.successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides.J Immunol,1994,152:2510-2519. [11] Ware R,Jiang H,Braunstein N,et al.Human CD8+ lymphocyte clones specific for T cell receptor V families expressed on autologous CD4+ T cells.Immunity,1995,2:177-184. |